Search

Your search keyword '"Morrison, Trista"' showing total 12 results
Start Over Author "Morrison, Trista"
12 results on '"Morrison, Trista"'

1. Financings Roundup

Author

Morrison, Trista

Subjects
Genoptix Inc. -- Securities, Electro Optical Sciences Inc. -- Investments, Community Health Systems Inc. -- Securities, Medical equipment and supplies industry -- Securities, Medical equipment and supplies industry -- Investments, Medical test kit industry -- Securities, Medical test kit industry -- Investments, Health care industry -- Securities, Going public (Securities), Company public offering, Health care industry, Company securities, Company investment, Health
Abstract

Financings Roundup Diagnostic lab Genoptix files for IPO of up to $86.25 million By TRISTA MORRISON Medical Device Daily Staff Writer with Medical Device Daily Staff Reports Genoptix (Carlsbad, California), [...]

Published
2007

2. Panel sees barriers as looming tall between bench and beside

Author

Morrison, Trista

Subjects
Medical research -- Conferences, meetings and seminars, Medicine, Experimental -- Conferences, meetings and seminars, Health, American Academy of Orthopaedic Surgeons -- Conferences, meetings and seminars
Abstract

American Academy of Orthopaedic Surgeons Meeting Panel sees barriers as looming tall between bench and beside By TRISTA MORRISON Medical Device Daily Staff Writer SAN DIEGO -- The American Heritage [...]

Published
2007

3. The Ps and Qs of getting products past FDA maze

Author

Morrison, Trista

Subjects
United States. Food and Drug Administration -- Management, Drug approval -- Evaluation, Drugs -- Product/Service Evaluations, Company business management, Banking, finance and accounting industries, Biotechnology industry
Abstract

Last week marked the end of approvable and not-approvable letters, as the FDA's Center for Drug Evaluation and Research adopted the Center for Biologics Evaluation and Research standard of issuing [...]

Published
2008

4. Cancer vaccine contenders lurk among the casualties

Author

Morrison, Trista

Subjects
Oxford BioMedica PLC -- Product development, Cancer vaccines -- Product development, Pharmaceutical industry -- Product development, Banking, finance and accounting industries, Biotechnology industry, TroVax (Vaccine) -- Product development
Abstract

Between the negative Phase III news on Oxford BioMedica plc's TroVax and the positive Phase III news on Biovest International Inc.'s BiovaxID, it's been a big month for cancer vaccines. [...]

Published
2008

5. Miscommunication matters: Vanda falls despite success

Author

Morrison, Trista

Subjects
Pharmaceutical industry -- Market share, Pharmaceutical industry -- Conferences, meetings and seminars, Teleconferencing, Company market share, Banking, finance and accounting industries, Biotechnology industry
Abstract

When Vanda Pharmaceuticals Inc. released Phase III data showing that insomnia drug tasimelteon (VEC-162) met its primary endpoint of improving short-term sleep onset, the company's stock popped in early trading [...]

Published
2008

6. PFS coming into its own, but just one factor in Avastin ok

Author

Morrison, Trista

Subjects
United States. Food and Drug Administration -- Management, Genentech Inc. -- Product development, Biological products industry -- Product development, Drugs -- Licensing, certification and accreditation, Company business management, Banking, finance and accounting industries, Biotechnology industry, Avastin (Medication) -- Licensing, certification and accreditation
Abstract

Now that the initial surprise has worn off regarding the FDA's decision to grant accelerated approval for Genentech Inc.'s Avastin (bevacizumab) in breast cancer, the industry can begin to digest [...]

Published
2008

7. Combo drugs prepare to tap underserved obesity market

Author

Morrison, Trista

Subjects
Phase II (San Bruno, California), Obesity -- Drug therapy, Obesity -- Prevention, Drug therapy, Combination, Banking, finance and accounting industries, Biotechnology industry
Abstract

Feeling guilty about all that Valentine's Day chocolate you polished off last weekend? Chances are you're not the only one who overindulged. The Centers for Disease Control and Prevention estimates [...]

Published
2008

8. Denosumbab may hold key for an Amgen recovery?

Author

Morrison, Trista

Subjects
Amgen Inc. -- Company sales and earnings, Merck & Company Inc. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Osteoporosis, Company earnings/profit, Banking, finance and accounting industries, Biotechnology industry, Fosamax (Medication)
Abstract

Although still trading near its 52-week low, Amgen Inc. got a boost at the end of January thanks to better than expected earnings and new data showing that osteoporosis drug [...]

Published
2008

9. Cytos signs $139m deal with Pfizer for Immunodrug vaccines

Author

Morrison, Trista

Subjects
Cytos Biotechnology AG -- Product development, Pfizer Inc. -- Product development, Biological products industry -- Product development, Pharmaceutical industry -- Product development, Vaccines -- Product development, Biotechnology industry, Business, Business, international
Abstract

As three of its own Immunodrug vaccine candidates advance through clinical trials, Cytos Biotechnology AG signed a CHF150 million (US$139 million) technology deal with Pfizer Inc.'s vaccine unit. The exclusive, [...]

Published
2008

10. LSD deal brings Amicus $50m now, $390m later

Author

Morrison, Trista

Subjects
Amicus Therapeutics Inc. -- Reports, Lazard Capital Markets L.L.C. -- Reports, Biotechnology industry -- Reports, Securities industry -- Reports, Securities industry, Biotechnology industry, Business, Business, international
Abstract

In a deal that could top $440 million, Amicus Therapeutics Inc. teamed up with Shire Human Genetic Therapies Inc. on the ex-U.S. development and commercialization of Amicus's three lead pharmacological [...]

Published
2007

11. Renovo licenses Juvista to shire in potential $825m deal

Author

Morrison, Trista

Subjects
Renovo Ltd. -- Licensing agreements, Shire Pharmaceuticals Group PLC -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Biotechnology industry, Business, Business, international
Abstract

When Renovo Group plc went public in April, CEO and Founder Mark Ferguson promised investors he'd have a partner for the anti-scarring drug Juvista in about a year. Ferguson delivered [...]

Published
2007

12. Affymetrix partnering with 30 European research centers

Author

Morrison, Trista

Subjects
Affymetrix Inc. -- Alliances and partnerships, Biotechnology industry -- Alliances and partnerships, Cancer -- Genetic aspects, Cancer -- Research, Oncology, Experimental, Biotechnology industry, Business, Business, international
Abstract

The opening plenary session at the American Association for Cancer Research annual meeting in Los Angeles focused on how the decreasing costs and increasing capabilities of gene sequencing technologies are [...]

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results